STAT3 and myeloid sarcoma: Inhibition of the JAK/STAT3 pathway attenuates clinical symptoms, reduces immune cell infiltration in the CNS, and decreases pro-inflammatory cytokine and chemokine expression in animal models of MS (Liu et al., 2014).